Back
EGFR-mutated mNSCLC: Updates from WCLC 2025
Experts discuss key WCLC updates in the diagnosis and treatment of EGFR-mutated NSCLC. The conversation highlights patient burden with frontline combination regimens and reviews pivotal data from the MARIPOSA and FLAURA2 trials.
EGFR-mutated mNSCLC: Updates from WCLC 2025
Episodes
All
All
Advertisement
Advertisement
Trending on OncLive
1
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
2
EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options
3
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
4
Frontline Choice Anchors Sequencing Decisions in EGFR-Mutated NSCLC
5